Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2024
Discovery & Translation
Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 19, 2019
Targets & Mechanisms
The next wave in neurodegeneration expands beyond neurons
Why modulating microglia could give drug developers a new handle on neurodegeneration
BioCentury | Jul 11, 2017
Emerging Company Profile
Complementary ALS play
Why Alsonex is targeting the complement system at C5a to treat ALS
BioCentury | Dec 15, 2014
Strategy
Momenta moving on
Why Momenta abandoning complex generics in favor of novel drugs and biosimilars
BioCentury | Aug 18, 2014
Finance
Flagship's fashion
How Flagship generates returns on early stage, disruptive platform plays
BioCentury | Mar 11, 2013
Emerging Company Profile
FPRT Bio: Neutralizing neuroinflammation
FPRT Bio's soluble TNF mimic blocks inflammation that drives ALS and PD
BioCentury | Oct 29, 2012
Emerging Company Profile
Regenesance: Stopping the MAC attack
Regenesance developing anti-C6 mAbs for myasthenia gravis
Items per page:
1 - 10 of 18